(Q37867784)

24 August 2017

1 reference

title

Emerging targets and treatments in amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

24 August 2017

0 references

2

Merit Cudkowicz

1 reference

24 August 2017

Lorne Zinman

1

1 reference

24 August 2017

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

10

1 reference

24 August 2017

5

1 reference

24 August 2017

481-490

1 reference

Epidemiology of ALS in Italy: a 10-year prospective population-based study.

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Induction of protective immunity by vaccination with wild-type apo superoxide dismutase 1 in mutant SOD1 transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Antisense oligonucleotide therapy for neurodegenerative disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Stem cell treatment in Amyotrophic Lateral Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Stem-cell transplantation into the frontal motor cortex in amyotrophic lateral sclerosis patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A randomized, placebo-controlled trial of memantine for functional disability in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Aggregation and Motor Neuron Toxicity of an ALS-Linked SOD1 Mutant Independent from Wild-Type SOD1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Up-regulation of protein chaperones preserves viability of cells expressing toxic Cu/Zn-superoxide dismutase mutants associated with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

The heat-shock response

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Impairment of fast axonal transport in the proximal axons of anterior horn neurons in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Ultrastructure of atrophic muscle in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Morphometry of the degenerative process in the hypoglossal nerves in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Up‐regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Mitochondrial respiratory chain function in skeletal muscle of ALS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Visualization of defective mitochondrial function in skeletal muscle fibers of patients with sporadic amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Misfolded mutant SOD1 directly inhibits VDAC1 conductance in a mouse model of inherited ALS

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Minocycline delays disease onset and mortality in a transgenic model of ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A clinical trial of creatine in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A randomized sequential trial of creatine in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

R+ pramipexole as a mitochondrially focused neuroprotectant: initial early phase studies in ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

KNS-760704 [(6R)-4,5,6,7-tetrahydro-N6-propyl-2, 6-benzothiazole-diamine dihydrochloride monohydrate] for the treatment of amyotrophic lateral sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its nondopaminergic enantiomer SND919CL2x [(+)2-amino-4,5,6,7-tetrahydro-6-Lpropylamino-benzathiazole dihydrochloride].

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis or motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Subcutaneous IGF-1 is not beneficial in 2-year ALS trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the -2578AA genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Focused ultrasound for blood-brain disruption and delivery of therapeutic molecules into the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Advances in stem cell research for Amyotrophic Lateral Sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Recovery from paralysis in adult rats using embryonic stem cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Wild-Type Nonneuronal Cells Extend Survival of SOD1 Mutant Motor Neurons in ALS Mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Is it too soon for mesenchymal stem cell trials in people with ALS?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Regulation of muscle growth by multiple ligands signaling through activin type II receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Extracellular regulators of axonal growth in the adult central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Nogo expression in muscle correlates with amyotrophic lateral sclerosis severity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

The neurite outgrowth inhibitor Nogo-A promotes denervation in an amyotrophic lateral sclerosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Lost in translation: treatment trials in the SOD1 mouse and in human ALS.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Excellent inter‐rater, intra‐rater, and telephone‐administered reliability of the ALSFRS‐R in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

The ALSFRSr predicts survival time in an ALS clinic population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

Design of phase II ALS clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2811%2970024-2

7 January 2021

10.1016/S1474-4422(11)70024-2

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21511200